Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Mike Ward
Emerging Company Profile: Rexgenero is developing a cell therapy to treat critical limb ischemia and is in the process of raising €25m to fund the Phase III program on top of €60m the company has raised to date. CEO Joe Dupere spoke with Scrip's Mike Ward at the Biotech Showcase last month.
Emerging Company Profile: Using cocktails of bacteriophages to attack bacterial infections, San Diego-based AmpliPhi has made progress in Phase I studies for its lead program. CEO Scott Salka explains to Mike Ward how he is looking to secure sufficient capital to support the Phase II development of AmpliPhi's lead program against chronic rhinosinusitis while advancing other product candidates.
Bolstered with a successful launch in Germany and the UK of its anemia treatment Feraccru, Shield Therapeutics is looking to expand both the label and its market reach.
As J&J announced the establishment of its eighth JLABS facility, Melinda Richter, head of J&J Innovation, JLABS, says that the company is actively looking to establish JLABS in Europe and Asia.
Emerging Company Profile: Tarveda Therapeutics has refocused during the past 18 months on its Pentarin technology. The company has raised $91.8m to date, including a recent $30m Series D round, which it will use to produce human data that could make it attractive to investors or pharma partners.
Keryx plans to expand Aurexia’s label to treat iron deficiency in pre-dialysis patients while searching for additional nephrology assets during 2017.